BridgeMD
New treatment option for Pneumonia Childhood
Official title The Role of Melatonin as an Adjuvant Therapy in Childhood Pneumonia
ClinicalTrials.gov ID: NCT06949904
What this study is testing
What is Melatonin?
Melatonin is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for pneumonia childhood.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this study is to compare the mean length of hospital stay between children with pneumonia receiving melatonin as an adjuvant therapy and those receiving standard of care alone. The hypothesis is that combining oral melatonin with standard treatment can reduce the length of hospital stay as compared to standard of care alone.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 1 to 12
You may be able to join if
- 1 month to 12 years
- Both genders
- Patient diagnosed as having pneumonia or severe pneumonia according to WHO definition
You likely can't join if
- Hospitalized within 14 days prior to the study
- Known TB exposure
- Active varicella or herpes simplex infection
- Allergy to the study medication
- Currently taking melatonin
- Any non pneumonia acute medical illness which requires antibiotic treatment as per local standard of care
See the full eligibility criteria
- 1 month to 12 years
- Both genders
- Patient diagnosed as having pneumonia or severe pneumonia according to WHO definition
- Hospitalized within 14 days prior to the study
- Known TB exposure
- Active varicella or herpes simplex infection
- Allergy to the study medication
- Currently taking melatonin
- Any non pneumonia acute medical illness which requires antibiotic treatment as per local standard of care
- Galactose intolerance, the lapp-lactase deficiency or glucose-galactose malabsorption
- Significant co-morbid disease: lung, cardiac, immune, liver, endocrine, neurological or psychiatric
The study team makes the final eligibility decision.
Where it's taking place
- Islamabad, Islamabad, Pakistan
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 1 month to 12 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Islamabad, Islamabad, Pakistan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.